Does Esketamine Work for Depression? A Balanced Guide to Spravato
- Sophroneo Psychiatry
- Jul 3
- 10 min read
Yes, esketamine can work for some adults with depression, especially treatment-resistant depression. But it is not a miracle treatment, and it is not the right fit for everyone. The most helpful way to understand Spravato, the brand name for esketamine nasal spray, is to hold two truths together: it is a real, FDA-approved depression treatment, and it also comes with limits, side effects, monitoring requirements, and access barriers.
Esketamine is used for certain adults with depression under medical supervision. According to the FDA-approved Spravato prescribing information, Spravato is indicated for treatment-resistant depression in adults, either as monotherapy or with an oral antidepressant. It is also indicated with an oral antidepressant for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
That does not mean every person with depression should receive esketamine. A licensed clinician must evaluate diagnosis, treatment history, safety risks, current medications, blood pressure, substance use history, and practical ability to complete in-clinic monitoring.
For mental health emergencies, please call 911.
Does esketamine work for depression?
Esketamine may reduce depressive symptoms in some adults, especially people whose depression has not improved enough after prior antidepressant treatment. The strongest use is for treatment-resistant depression, often shortened to TRD.
Treatment-resistant depression usually means depression that has not responded adequately to at least two appropriate antidepressant trials. This can feel discouraging, but it does not mean treatment is hopeless. It means the care plan may need a different approach.
Esketamine is different from standard antidepressants because it acts on the glutamate system, including NMDA receptor activity. Most older antidepressants work mainly through serotonin, norepinephrine, dopamine, or related pathways. Researchers are still studying exactly how esketamine improves depressive symptoms.
A careful summary:
Question | Balanced answer |
Does esketamine work for some people? | Yes, clinical trials and FDA approval support its use for specific adult depression indications. |
Does it work for everyone? | No. Some patients respond, some partially improve, and some do not respond. |
Is it a first step for most depression? | Usually no. It is typically considered after other treatments have not helped enough. |
Is it taken at home? | No. Spravato is administered in a certified healthcare setting with monitoring. |
Can it replace a full care plan? | Not usually. Many patients still need therapy, medication management, safety planning, or other support. |
If depression symptoms are part of your concern, a clinician can help you review depression treatment options and decide what level of care is appropriate.
What is esketamine, and how is it different from ketamine?
Esketamine is one part of the ketamine molecule and is formulated as a prescription nasal spray under the brand name Spravato. Ketamine and esketamine are related, but they are not identical treatments.
Ketamine is an older medication used in anesthesia and pain-related medical settings. Some clinics use intravenous ketamine off-label for depression. Spravato is the FDA-approved esketamine nasal spray used under a structured safety program for specific depression indications.
The National Institute of Mental Health overview of brain stimulation and rapid-acting treatments notes that ketamine-related treatments affect glutamate, a chemical messenger involved in brain signaling. However, patients should not assume that all ketamine-related treatments have the same approval status, safety requirements, insurance coverage, or evidence base.
Treatment | What it is | Important distinction |
Spravato | Esketamine nasal spray | FDA-approved for specific adult depression indications and given in a certified healthcare setting |
IV ketamine | Ketamine given by infusion | Often used off-label for depression, depending on the clinic and patient situation |
Oral or compounded ketamine | Ketamine prepared in other forms | Not the same as FDA-approved Spravato for depression |
Standard antidepressants | Medications such as SSRIs, SNRIs, or other classes | Usually taken at home and often tried before advanced options |
A licensed clinician can help determine what is appropriate. Do not change medication without guidance from your prescriber.
Who may be considered for Spravato?
Spravato may be considered for certain adults with treatment-resistant depression or adults with major depressive disorder and acute suicidal ideation or behavior, depending on the clinical situation and FDA-approved indication.
A patient may need a careful review of:
Depression diagnosis and symptom severity
Prior antidepressant trials
Current medications
Blood pressure and cardiovascular history
Substance use history
History of psychosis, mania, or dissociation
Pregnancy status or pregnancy planning
Transportation after treatment
Ability to remain for post-dose monitoring
Insurance or private-pay considerations
This is why a psychiatric evaluation is important before advanced depression treatments are considered. The goal is not simply to match a person to a medication. The goal is to understand the full clinical picture.
What does the research say about esketamine?
The research supports esketamine as a treatment option for some adults with treatment-resistant depression, but the evidence is more nuanced than many headlines suggest.
Short-term symptom improvement
Clinical trials have shown that esketamine can reduce depressive symptoms in some adults with treatment-resistant depression. The FDA label reflects that Spravato is approved for TRD in adults, now either alone or with an oral antidepressant.
That matters because many people with TRD have already tried multiple treatments without enough improvement. For some, a treatment with a different mechanism may offer another option.
Still, trial averages do not predict one person’s outcome. A meaningful result in a study does not mean every patient will experience remission, rapid improvement, or lasting benefit.
Relapse prevention and maintenance treatment
Longer-term data also suggest that continuing esketamine may help some patients maintain benefit after they respond. The SUSTAIN-1 relapse-prevention study found that continuing esketamine nasal spray plus an oral antidepressant delayed relapse compared with switching to placebo nasal spray plus an oral antidepressant among patients who had already achieved stable remission or stable response.
This is encouraging, but it has an important limitation. A relapse-prevention study mainly tells us what happened among people who had already responded or remitted. It does not prove that every person starting esketamine will respond.
What the evidence does not prove
The evidence does not prove that esketamine is best for every person with depression. It also does not remove the need for careful monitoring, therapy support, medication review, or safety planning.
The most accurate message is not “Spravato is overhyped” or “Spravato is a miracle.” The accurate message is: Spravato is a legitimate option for specific patients, but expectations should be realistic.
What are common esketamine side effects?
Esketamine can cause side effects that may feel very different from standard antidepressant side effects. Some people tolerate treatment well. Others find the experience uncomfortable or treatment-limiting.
The Spravato REMS program exists because esketamine can cause sedation, dissociation, respiratory depression, and other safety concerns that require observation after dosing.
Common or clinically important concerns may include:
Possible side effect or concern | What it may feel like | What to do |
Dissociation | Feeling detached from your body, surroundings, or time | Tell staff if it feels distressing |
Sedation | Sleepiness, slowed reaction time, or heavy fatigue | Plan not to drive after treatment |
Dizziness | Feeling lightheaded or unsteady | Stand slowly and follow clinic instructions |
Nausea | Queasiness or vomiting risk | Ask the clinic what to expect before dosing |
Blood pressure increase | May not be felt physically | Blood pressure monitoring is part of care |
Anxiety during the experience | Feeling unsettled or afraid | Tell staff immediately |
Headache or unpleasant taste | Physical discomfort or bitterness | Ask about safe management strategies |
Side effects, benefits, and treatment fit can vary.
Why does Spravato require in-clinic monitoring?
Spravato requires in-clinic monitoring because of safety risks after dosing. Patients self-administer the nasal spray under supervision in a certified healthcare setting, then remain under observation before they can leave.
The Spravato REMS program overview states that patients must be monitored for at least two hours after administration for resolution of sedation, dissociation, respiratory depression, and changes in vital signs.
This requirement is medically important, but it can also be practically difficult. Patients may need:
Reliable transportation
Time away from work, school, caregiving, or other responsibilities
A ride home after each session
Insurance authorization or private-pay planning
A certified treatment site within reasonable distance
Enough flexibility to complete repeated visits
This is one reason Spravato is not just “a nasal spray.” It is a monitored treatment process.
Is esketamine overhyped?
Esketamine can be overhyped when it is described as a guaranteed breakthrough, a quick fix, or a treatment that works for nearly everyone. That language can harm patients by creating unrealistic expectations.
A balanced view is better:
Overhyped claim | More accurate framing |
“Esketamine cures depression.” | Esketamine may help some adults with specific depression indications. |
“It works immediately for everyone.” | Some people may experience early improvement, but response varies. |
“It is just ketamine you can take at home.” | Spravato is administered under supervision in a certified healthcare setting. |
“If nothing else worked, this definitely will.” | It is one option among several for treatment-resistant depression. |
“Side effects are no big deal.” | Dissociation, sedation, blood pressure changes, and monitoring needs matter. |
Patients deserve hope, but they also deserve accuracy. It is possible to be encouraged by esketamine without exaggerating what it can do.
Decision-support table: Is Spravato worth asking about?
Use this table as a conversation guide, not as a diagnosis or treatment recommendation.
Your situation | Is Spravato worth asking about? | Why |
You have tried multiple antidepressants without enough relief | Yes, ask a clinician | Spravato may be considered for treatment-resistant depression |
You have depression with acute suicidal thoughts or behavior | Seek urgent care first | For mental health emergencies, please call 911. |
You cannot arrange transportation after treatment | Ask before starting | Patients should not drive after dosing |
You have uncontrolled high blood pressure | Requires careful review | Spravato can raise blood pressure |
You have a history of substance use disorder | Requires careful review | Esketamine is a controlled substance and needs monitoring |
You are hoping for a guaranteed cure | Reset expectations | No depression treatment works for everyone |
You want an option that is not taken daily at home | Possibly | Spravato is administered in clinic, but still requires repeated visits |
You are comparing Spravato, TMS, or ketamine | Yes, ask for a full comparison | Different treatments have different evidence, logistics, and side effects |
For patients comparing advanced options, it may also be useful to review NeuroStar TMS, which is a non-drug therapy for major depressive disorder when antidepressants have not helped enough.
Troubleshooting: Questions to ask before treatment
Before starting Spravato, bring practical and medical questions to your appointment. Good questions can protect you from confusion later.
Concern | What to ask |
I am not sure I qualify | Do my symptoms and treatment history meet criteria for Spravato? |
I am worried about side effects | What side effects are common, and when should I call the clinic? |
I have high blood pressure | How will my blood pressure be monitored before and after dosing? |
I have trauma or panic symptoms | What happens if dissociation feels frightening? |
I take other medications | Are there interactions or safety issues to review? |
I need to work after treatment | What should I expect on treatment days? |
I do not have transportation | What are the clinic’s requirements for leaving after treatment? |
I am unsure about cost | What insurance verification or private-pay information should I confirm? |
I do not respond | What is the next step if Spravato does not help enough? |
Coverage can vary. Confirm benefits with Sophroneo or your insurance provider.
How Sophroneo fits
Sophroneo Behavioral Health & TMS can help patients and families consider Spravato as part of a broader depression care plan, not as a one-size-fits-all answer.
How Sophroneo may fit:
Spravato esketamine therapy is available for treatment-resistant depression and is administered in clinic with safety monitoring.
Psychiatric evaluations, medication management, and therapy are available for children, adolescents, adults, and families.
Medication management may help review prior antidepressant trials, side effects, and next-step options.
Telepsychiatry is available for appropriate visits.
Care is available in Powder Springs/Austell and Stone Mountain.
Sophroneo participates in most major insurance plans and accepts private pay. Coverage can vary. Confirm benefits with Sophroneo or your insurance provider.
Patients who want to understand whether Spravato, TMS, therapy, or another treatment path may fit can review Sophroneo’s Spravato specialist information or broader behavioral health services.
Sophroneo’s verified locations are 4170 Old Austell Rd, Powder Springs, GA 30127, and 5300 Memorial Dr Suite 219B, Stone Mountain, GA 30083. The phone number is 770-999-9495.
Assumptions and limitations
This article assumes the reader is asking about esketamine for depression, especially treatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior. It does not diagnose depression or determine whether Spravato is appropriate for any specific person.
Important limitations:
Esketamine does not work for everyone.
Spravato is not a replacement for emergency mental health care.
Spravato requires in-clinic administration and monitoring.
Side effects can include dissociation, sedation, dizziness, nausea, and blood pressure changes.
Access may depend on insurance, transportation, scheduling, and certified treatment availability.
Some patients may still need therapy, medication management, TMS, ECT discussion, hospitalization, or other treatment options.
A licensed clinician should review the full medical and mental health history before recommending Spravato.
Frequently Asked Questions:
Does Spravato work for treatment-resistant depression?
Spravato can help some adults with treatment-resistant depression, but it does not work for everyone. It is best understood as one evidence-based option for certain patients whose depression has not improved enough with prior antidepressant treatment.
Is esketamine FDA-approved?
Yes. Spravato, the brand name for esketamine nasal spray, is FDA-approved for treatment-resistant depression in adults, either as monotherapy or with an oral antidepressant. It is also approved with an oral antidepressant for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
How fast can esketamine work?
Some patients may experience improvement earlier than with standard antidepressants, but timing varies. Early improvement does not happen for everyone, and ongoing treatment planning is still important.
What are the most common esketamine side effects?
Common or important side effects may include dissociation, sedation, dizziness, nausea, blood pressure increases, headache, unpleasant taste, and feeling disconnected or strange during treatment. Your treatment team should explain what to expect before starting.
Can I drive after Spravato treatment?
No. Patients should not drive after Spravato treatment on the same day. Because sedation and dissociation can occur, patients need transportation planning after each session.
Is Spravato the same as ketamine infusion?
No. Spravato is esketamine nasal spray and is FDA-approved for specific depression indications under a REMS program. Ketamine infusions use racemic ketamine and are commonly used off-label for depression. Approval status, setting, insurance coverage, and protocols differ.
Can Spravato replace antidepressants or therapy?
Sometimes Spravato may be used as monotherapy for treatment-resistant depression in adults, depending on the clinical situation and current FDA labeling. However, many patients still need therapy, medication management, safety planning, or other supports. Do not change medication without guidance from your prescriber.
How long do people stay on Spravato?
Treatment length varies. Some patients receive an initial course and then continue with maintenance treatment if they respond and tolerate it. Others stop because of side effects, logistics, cost, lack of response, or a clinician’s recommendation.
What should I ask before starting Spravato?
Ask whether you meet criteria, what benefits are realistic, what side effects to expect, how blood pressure is monitored, whether you need a ride home, how progress will be measured, what insurance may cover, and what the next step would be if Spravato does not help enough.
If depression has not improved enough with previous treatment, consider scheduling an appointment to discuss whether Spravato, TMS, therapy, medication management, telepsychiatry, or another care option may be appropriate for your situation.
Comments